| Income Statement | 2024-09-30 | |||
|---|---|---|---|---|
| Revenue from contract with customer, excluding assessed tax | 52 | |||
| Research and development expense | 3,165 | |||
| General and administrative expense | 1,439 | |||
| Costs and expenses | 4,604 | |||
| Operating income (loss) | -4,552 | |||
| Loss on settlement of warrants | -1,106 | |||
| Change in fair value of warrant liabilities | 71 | |||
| Other nonoperating income (expense) | -3 | |||
| Income (loss) from continuing operations before income taxes, noncontrolling interest | -5,732 | |||
| Net loss attributable to vaccinex, inc. common stockholders | -5,732 | |||
| Basic eps | -2.83 | |||
| Diluted eps | -2.83 | |||
| Basic average shares | 2,026,920 | |||
| Diluted average shares | 2,026,920 | |||
VACCINEX, INC. (VCNX)
VACCINEX, INC. (VCNX)